EFFICACY AND SAFETY OF MICAFUNGIN ON THE MANAGEMENT OF INVASIVE FUNGAL INFECTIONS AMONG PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AT TERTIARY HOSPITALS IN GREECE- THE ASPIRE STUDY

EHA Library, Maria Kotsopoulou, 132733

ANTIRETROVIRAL THERAPY AND CHEMOTHERAPY IN PATIENTS WITH HIV INFECTION AND HAEMATOLOGICAL DISEASE - TOXICITY ASSESSMENT

EHA Library, Paula Cristina Gaspar Brandao de Sousa e Sant, 132734

RE-EVALUATING THE IMPACT OF INVASIVE ASPERGILLOSIS ON THE PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Marie-Pierre Ledoux, 132735

PRIMARY ANTIFUNGAL PROPHYLAXIS (PAP) WITH MICAFUNGIN AT THE DOSE 50MG PER DAY IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) DURING INDUCTION CHEMOTHERAPY: THE „REAL-LIFE“ EVALUATION

EHA Library, Tomas Kabut, 132736

COMPARISON OF DE-ESCALATION AND NON-DE-ESCALATION EMPIRICAL THERAPY FOR CONTROLLING INFECTION IN PATIENTS WITH SEVERE APLASTIC ANEMIA TREATED WITH ANTITHYMOCYTE GLOBULIN

EHA Library, Rong Fu, 132737

A RETROSPECTIVE ANALYSIS ABOUT STENOTROPHOMONAS MALTOPHILIA SEPSIS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY: A SINGLE CENTER STUDY FOR 12 YEARS

EHA Library, Maki Asahi, 132738

RIGOSERTIB (RIGO) COMBINED WITH AZACITIDINE (AZA) IN VITRO & CLINICAL: MODULATES EPIGENETIC EVENTS AND OVERCOMES CLINICAL RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Lewis Silverman, 132739

PREVALENCE AND DYNAMICS OF LEUKEMIA-ASSOCIATED MUTATIONS IN ELDERLY INDIVIDUALS WITHOUT HEMATOLOGIC DISORDERS

EHA Library, Thomas Ernst, 132740

FLOW CYTOMETRIC RESPONSE MONITORING IN MDS WITH DEL(5Q) USING A SIMPLE 5-PARAMETER-SCORE – A TWO-CENTER-EXPERIANCE

EHA Library, Uta OELSCHLAEGEL, 132741

ABT-199 EFFECTIVELY INDUCES APOPTOSIS IN HIGH-RISK MDS PROGENITOR CELLS IRRESPECTIVE OF PROGNOSTICALLY ADVERSE MUTATIONS OF TP53, EZH2, RUNX1, AND ASXL1

EHA Library, Johanna Kauschinger, 132742

DYNAMICS OF GENE EXPRESSION CHANGES IN THE DEVELOPMENT OF MYELODYSPLASTIC SYNDROMES AND EVOLUTION TO ACUTE MYELOID LEUKEMIA

EHA Library, Maria Hernandez Sanchez, 132743

BONE HOMEOSTASIS IS SIGNIFICANTLY ALTERED IN A MYELODYSPLASTIC SYNDROME MOUSE MODEL

EHA Library, Heike Weidner, 132744

GENETIC FACTORS ASSOCIATED WITH EVOLUTION OF MYELODYSPLASTIC SYNDROMES TO SECONDARY CHRONIC MYELOMONOCYTIC LEUKEMIA.

EHA Library, Ryunosuke Saiki, 132745

SCAPER AND RPRD1A: TWO NOVEL CANDIDATES IN THE PATHOGENESIS OF FAMILIAL PLATELET DISORDER WITH PROPENSITY TO DEVELOP MYELOID MALIGNANCIES (FPD/AML)

EHA Library, Majidi Majidi, 132746

REAL-TIME DEFORMABILITY CYTOMETRY (RT-DC) AS NOVEL DIAGNOSTIC TOOL IN MYELODYSPLASTIC SYNDROMES

EHA Library, Ekaterina Bulycheva, 132747

SPATIAL INTERACTION OF CYTOGENETIC AND MOLECULAR MUTATIONS IN MYELODYSPLASTIC SYNDROMES

EHA Library, Detlef Haase, 132748

MONUCLEAR MYELOID-DERIVED SUPPRESSOR CELLS (MO-MDSC) EXPANSION AND PROGRESSION IN MYELODYSPLASTIC SYNDROMES

EHA Library, Francisca Hernandez Mohedo, 132749

ABERRANT METHYLATION OF PROMOTER REGIONS OF SOX7, P15INK4B AND WNT PATHWAY ANTAGONIST GENES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Ivan Kostroma, 132750

IRON OVERLOAD-ASSOCIATED GENETIC INSTABILITY IN MYELODYSPLASTIC SYNDROME

EHA Library, Detlef Haase, 132751

CONVENTIONAL CYTOGENETICS, ACGH, AND PCR AS INTEGRATED WORKUP FOR A CORRECT DIAGNOSIS OF MDS.

EHA Library, Sara Galimberti, 132752

CLONAL DYNAMICS OF TWO DISTINCT CLONES IN LEUKEMIC TRANSFORMATION FROM MDS WITH ISOLATED DEL(5Q) HARBORING TP53 MUTATION

EHA Library, Hiroyuki Tsukamoto, 132753

THE DNA METHYLATION INHIBITORS AZACITIDINE AND DECITABINE ACTIVATE UNIQUE AND COMMON TRANSCRIPTIONAL PATHWAYS THAT INCLUDE POTENTIAL NOVEL MARKERS OF RESPONSE

EHA Library, Kathryn Clarke, 132754

INTEGRATED ANALYSIS OF BOTH BIOLOGICAL AND MOLECULAR EFFECTS OF THE EPIGENETIC MODIFYING AGENT ROMIDEPSIN IN MDS/AML

EHA Library, Kathryn Clarke, 132755

THERAPY RELATED MYELOID NEOPLASM FOLLOWING RADIOTHERAPY HAS HIGHER INCIDENCE OF POOR RISK CYTOGENETICS AND ARE ASSOCIATED WITH POOR SURVIVAL COMPARED TO DE NOVO MDS CASES

EHA Library, Deepak Singhal, 132756

POLY [ADP-RIBOSE] POLYMERASE 1 (PARP-1) EXPRESSION IS CORRELATED TO THE TYPE OF MYELODYSPLASTIC SYNDROME ACCORDING TO BOTH WHO CLASSIFICATION AND IPSS SCORE

EHA Library, Panagiotis Diamantopoulos, 132757

NEXT GENERATION SEQUENCING IN HIGH RISK MYELODYSPLASTIC SYNDROMES AND SECONDARY ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH AZACITIDINE ACCORDING TO HIGH RISK MDS 2009 PROTOCOL FROM CETLAM GROUP.

EHA Library, Marta Cabezón, 132758

MOLECULAR ALTERATIONS ASSOCIATED WITH PROGRESSION OF MYELODYSPLASTIC SYNDROMES TO SECONDARY CHRONIC MYELOMONOCYTIC LEUKEMIA.

EHA Library, Alessandro Sanna, 132759

COST CHANGES ASSOCIATED WITH ACHIEVING TRANSFUSION INDEPENDENCE (TI) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Amy Dezern, 132760

FERRITINE LEVEL AND PERFORMANCE STATUS ARE SIGNIFICATIVE PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN LOWER-RISK MDS PATIENTS GRUPO ARGENTINO DE ESTUDIO DE LOS SINDROMES MIELODISPLASICOS

EHA Library, Alicia Enrico, 132761

CHARACTERIZATION OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: ANALYSIS OF UNITED STATES COMMERCIAL CLAIMS DATABASE

EHA Library, Maneesha Mehra, 132762

MINIMAL RESIDUAL DISEASE MONITORING AND PREEMPTIVE IMMUNOTHERAPY IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Xiao-Dong Mo, 132763

PROGNOSTIC SIGNIFICANT OF ASXL1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES

EHA Library, Shao-Yuan Wang, 132764

CIRCULATING CLONAL CELLS ARE PLENTYFUL IN PERIPHERAL BLOOD OF PATIENTS WITH MYELODYSPLASTIC SYNDROME: A COMPARISON OF THE PERCENTAGE OF CLONAL CELLS IN PB AND BM BY FLUORESCENT IN SITU HYBRIDIZATION

EHA Library, Dong Soon Lee, 132765

TREATMENT-EMERGENT ADVERSE EVENTS IN LENALIDOMIDE-TREATED LOW/INT-1-RISK MYELODYSPLASTIC SYNDROMES PATIENTS WITHOUT DEL(5Q) INELIGIBLE FOR OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS

EHA Library, Antonio De Almeida, 132766

IMPACT OF PREVIOUS TRANSFUSION AND COMORBIDITIES IN THE IPSS-R FOR OVERALL SURVIVAL

EHA Library, Nicolas Diaz Varela, 132767

ANALYSIS OF P53 EXPRESSION BY IMMUNOHISTOCHEMISTRY AS AN ADDITIONAL PROGNOSTIC TOOL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, su maung, 132768

A PROGNOSTIC SCORING MODEL FOR PATIENTS TREATED WITH AZACITIDINE FOR MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIAS

EHA Library, Kazuya Sato, 132769

THE IMPORTANCE OF IMMUNOPHENOTYPING OF HEMOPOIETIC PRECURSORS IN THE DIAGNOSIS OF CHILDHOOD MDS

EHA Library, Irene Lorand-Metze, 132770

FAVORABLE OUTCOMES WITH TUMOR BURDEN REDUCTION WITH HYPOMETHYLATING AGENTS BEFORE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLNATATION FOR PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME

EHA Library, Sungwoo Park, 132771

DISCONTINUATION OF HYPOMETHYLATING AGENT, DOES IT BRING REDUCED SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME ?

EHA Library, Ho Sup Lee, 132772

HETEROGENEITY IN CYTOGENETIC AND CLINICAL FEATURES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND DELETION 5Q

EHA Library, Eleni Gavriilaki, 132773

VALUE OF THE MULTIPARAMETRIC FLOW CYTOMETRY IN LOW RISK MYELODYSPLASTIC SYNDROMES AND TYPE I CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Marcelo Iastrebner, 132774

СLINICAL AND HEMATOLOGICAL FEATURES OF PRIMARY MYELODYSPLASTIC SYNDROMES IN ADULTS AND CHILDREN

EHA Library, Natallia Klimkovich, 132775

IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?

EHA Library, Erden Atilla, 132776

CLINICAL CHARACTERISTICS OF PATIENTS WITH MYELOID NEOPLASMS FROM REGIONS CONTAMINATED BY DEPLETED URANIUM: 20 YEAR ANALYSIS

EHA Library, Amina Kurtovic-Kozaric, 132777

CLINICAL AND LABORATORIAL CHARACTERISTICS OF A COHORT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ERYTHROID HYPERPLASIA

EHA Library, Aining Sun, 132778

TP53 GENE MUTATIONS IMPACT ON OVERALL SURVIVAL OF PATIENTS TREATED WITH LOW-DOSE CLOFARABINE AS A SECOND LINE THERAPY DUE TO THEIR RESISTANCE TO AZACITIDINE

EHA Library, Thomas Braun, 132779

REPORT ON OUTCOME OF HYPOMETHYLATING THERAPY WITH ANALYSIS ON PROGNOSTIC VALUE OF REVISED-INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OF LOWER-RISK BASED ON IPSS

EHA Library, Yoo Jin Lee, 132780

SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY) SUBANALYSIS: IMPACT OF COMORBIDITIES AND CENTER LEVEL ON RESPONSE TO ESAS IN LOWER RISK MDS

EHA Library, Julio Davila Valls, 132781

IN MULTIPLE MYELOMA THERE ARE TWO SUBSETS OF IMMUNOSUPPRESSIVE POLYMORPHONUCLEAR NEUTROPHILS WITH INCREASED LEVELS OF ARGINASE

EHA Library, ALESSANDRA ROMANO, 132782

RESISTANCE TO PROTEASOME INHIBITORS IS MEDIATED BY AN OVER-ACTIVATION OF THE UPR AND THE DNA DAMAGE RESPONSE IN A PRECLINICAL MODEL OF MM

EHA Library, Enrique M Ocio, 132783

DEREGULATION OF A-TO-I RNA EDITING IS FUNCTIONALLY AND CLINICALLY RELEVANT IN MULTIPLE MYELOMA

EHA Library, Phaik Ju Teoh, 132784

TARGETING PROTEIN KINASE CK1A IN THE BONE MARROW MICROENVIRONMENT: A NEW POSSIBLE THERAPEUTIC APPROACH FOR MULTIPLE MYELOMA THERAPY?

EHA Library, Marilena Carrino, 132785

RHOU GTPASE: A NOVEL POTENTIAL TARGET TO DISRUPT MULTIPLE MYELOMA PLASMA CELL INTERACTION WITH PROTECTIVE BONE MARROW NICHES

EHA Library, Sara Nunes, 132786

DEREGULATION OF MAJOR DNA REPAIR MECHANISMS CORRELATES WITH CLINICAL OUTCOME OF ANTI-MYELOMA THERAPY. THE BENEFICIAL EFFECT OF DNA REPAIR INHIBITION

EHA Library, Maria Gkotzamanidou, 132787

BAX ACTIVATION IS A POTENTIAL BIOMARKER OF RESPONSE TO FILANESIB (ARRY-520) ALONE AND IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE

EHA Library, Enrique M Ocio, 132788

COMBINATION DRUG THERAPIES WITH THE NOVEL RNA POLYMERASE I INHIBITOR CX-5461 IMPROVE EFFICACY IN THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Kylee Maclachlan, 132789

CHARACTERIZATION OF A PERK KINASE INHIBITOR WITH ANTI-MYELOMA ACTIVITY

EHA Library, Efstathios Kastritis, 132790

EXPLORING THE BONE MARROW NICHE IN MULTIPLE MYELOMA USING AN ADHESION-INDEPENDENT THREE-DIMENSIONAL CO-CULTURE MODEL

EHA Library, Johannes Moritz Waldschmidt, 132791

ACTIVATION OF TOLL-LIKE RECEPTOR 4 PROMOTES MULTIPLE MYELOMA CELL GROWTH AND SURVIVAL THROUGH UPR PATHWAY AND IN A CASPASE-DEPENDENT MANNER.

EHA Library, Efstathios Kastritis, 132792

LONG NON-CODING RNA MALAT1 WAS ASSOCIATED WITH PROGRESSION OF MULTIPLE MYELOMA AND INDUCED BY CELLULAR STRESS

EHA Library, Hiroshi Handa, 132793

COMBINATION OF T(4;14), DEL(17P13), DEL(1P32) AND 1Q21 GAIN FISH PROBES IDENTIFIES CLONAL HETEROGENEITY AND ENHANCES DETECTION OF ADVERSE CYTOGENETIC PROFILES IN 233 NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Thomas Smol, 132794

EXPRESSION OF HUMAN CRBN SENSITIZES MOUSE MULTIPLE MYELOMA CELLS TO LENALIDOMIDE

EHA Library, Dilan Serdar, 132795

INFLUENCE OF HISTONE DEACETYLASE INHIBITORS (HDACIS) ON THE EXPRESSION OF ADHESION MOLECULES AND MODERN TARGET STRUCTURES IN MULTIPLE MYELOMA (MM)

EHA Library, Stefan Müller, 132796

HEME OXYGENASE 1 (HO-1) PROTECTS MYELOMA CELLS AGAINST BORTEZOMIB THROUGH NUCLEAR TRANSLOCATION AND REGULATION OF ER STRESS AND AUTOPHAGY PROTEINS

EHA Library, Daniele Tibullo, 132797

ANTI-MYELOMA EFFECT OF CANNABINOIDS

EHA Library, Jose Antonio Perez-Simon, 132798

BONE MARROW ADIPOCYTES PROMOTE MYELOMA CELL PROLIFERATION THROUGH INTERLEUKIN-6 SIGNALLING

EHA Library, Alvin Katumba, 132799

RETROSPECTIVE STUDY OF PARAPROTEINEMIA PREVALENCE AND DEVELOPMENT OF HEMATOLOGICAL MALIGNANCIES IN HBSAG POSITIVE VERSUS HBSAG NEGATIVE PATIENTS

EHA Library, Radha Raghupathy, 132800

PROTEOMIC SIGNATURE PREDICTING COMPLETE RESPONSE TO PAD IN REFRACTORY MULTIPLE MYELOMA PATIENTS QUALIFIED FOR AUTOPBSCT AND VD CONSOLIDATION – MULTICENTER, POLISH MYELOMA CONSORTIUM 001 STUDY

EHA Library, Dominik Dytfeld, 132801

NOTCH PATHWAY AND INTELEUKIN-6 COOPERATE TO SUPPORT MULTIPLE MYELOMA CELL PROLIFERATION

EHA Library, Serena Galletti, 132802

INTEGRATIVE ANALYSIS OF DNA COPY NUMBER, DNA METHYLATION AND GENE EXPRESSION IN MULTIPLE MYELOMA REVEALS ALTERATIONS RELATED TO RELAPSE.

EHA Library, Patryk Krzeminski, 132803

DETAILED FISH PROFILING OF MULTIPLE MYELOMA PATIENTS IDENTIFIES A GROUP OF PATIENTS WITH ONLY SECONDARY CHROMOSOMAL ABERRATIONS

EHA Library, Milena Pantic, 132804

LONG NON-CODING RNAS IN MULTIPLE MYELOMA

EHA Library, Veronika Kubaczková, 132805

NEXT GENERATION FLOW CYTOMETRY IS A RELIABLE TECHNIQUE FOR DETECTING MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS IN COMPLETE REMISSION: A STUDY COMPARING SHORT VS LONG TERM REMISSION

EHA Library, Alessandro Gozzetti, 132806

BONE DISEASE IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE:RESULTS FROM A SCREENED POPULATION-BASED STUDY

EHA Library, Sigrún Thorsteinsdóttir, 132807

COMPENSATORY STRESS PATHWAYS IN MODULATING ER STRESS IN BORTEZOMIB RESISTANT MULTIPLE MYELOMA.

EHA Library, Nicholas Nikesitch, 132808

CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY

EHA Library, Sara Bringhen, 132809

AN ONGOING MULTINATIONAL OBSERVATIONAL STUDY IN MULTIPLE MYELOMA (PREAMBLE): PRELIMINARY REPORT ON PROGRESSION-FREE SURVIVAL

EHA Library, Teresa Zyczynski, 132810

ROBUSTNESS OF THE PROGNOSTIC VALUE OF THE SKY92 MARKER VERSUS FISH MARKERS ACROSS NINE MULTIPLE MYELOMA COHORTS

EHA Library, Martin van Vliet, 132811

DARATUMUMAB MONOTHERAPY COMPARED WITH REAL-WORLD HISTORICAL CONTROL DATA IN HEAVILY PRETREATED PATIENTS WITH HIGHLY REFRACTORY MULTIPLE MYELOMA: AN ADJUSTED TREATMENT COMPARISON

EHA Library, Joris Diels, 132812

IMPACT OF FAMILY HISTORY ON RISK OF PROGRESSION OF MGUS TO MULTIPLE MYELOMA: A POPULATION-BASED STUDY

EHA Library, Kristrún Aradóttir, 132813

The Swedish Multiple Myeloma Registry: Median survival exceeds 7 years in patients 65 years and younger, population-based data on 3,876 multiple myeloma patients diagnosed 2008-2013

EHA Library, Cecilie Blimark, 132814

CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE: SUBGROUP ANALYSIS OF THE PHASE 3 ENDEAVOR STUDY TO EVALUATE THE IMPACT OF PRIOR TREATMENT ON PATIENTS WITH RELAPSED MULTIPLE MYELOMA

EHA Library, Philippe Moreau, 132815

CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE: SUBGROUP ANALYSIS OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY BASELINE CYTOGENETIC RISK STATUS (PHASE 3 ENDEAVOR STUDY)

EHA Library, Hartmut Goldschmidt, 132816

INCREASED LEVELS OF SOLUBLE SYNDECAN-1 AND LDH ARE MAJOR PROGNOSTIC FACTORS FOR SUBSEQUENT OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL AFTER A RELAPSE IN MULTIPLE MYELOMA

EHA Library, Xenofon Papanikolaou, 132817

11C- METHIONINE PET SCAN FOR THE DETECTION OF MULTIPLE MYELOMA LESIONS

EHA Library, Rocío Figueroa Mora, 132818

ACY-241, A NOVEL, ORAL TABLET HDAC6 SELECTIVE INHIBITOR COMBINES SAFELY WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (ACE-MM-200 STUDY)

EHA Library, Ruben Niesvizky, 132819

TREATMENT OF PRE-MYELOMA STATES: A CLINICAL DECISION ANALYSIS

EHA Library, David Liu, 132820

PHASE I/IIA CLINICAL STUDY OF AUTOLOGOUS DENDRITIC CELL THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Je-Jung Lee, 132821

ECONOMIC EVALUATION OF CARFILZOMIB+LENALIDOMIDE+DEXAMETHASONE (KRD) VS. LENALIDOMIDE+DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)

EHA Library, Sumeet Panjabi, 132822

CARFILZOMIB AND DEXAMETHASONE VS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: ANALYSIS OF THE PHASE 3 ENDEAVOR STUDY BY AGE SUBGROUP

EHA Library, Antonio Palumbo, 132823

TREATMENT AND OUTCOME PATTERNS IN PATIENTS WITH RELAPSED WALDENSTRÖM’S MACROGLOBULINEMIA: DEVELOPMENT OF A LARGE OBSERVATIONAL PAN-EUROPEAN DATA PLATFORM

EHA Library, Christian Buske, 132824

EFFICACY AND SAFETY OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: IMPACT OF PRIOR THERAPY IN THE PHASE 3 TOURMALINE-MM1 STUDY

EHA Library, Maria Victoria Mateos, 132825

PRACTICE PATTERNS AND OUTCOMES IN U.S. PATIENTS (PTS) WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA (RRMM) AND COMORBID RENAL DYSFUNCTION (RD) AND/OR CARDIOVASCULAR DISEASE (CVD)

EHA Library, Candice Yong, 132826

BORTEZOMIB-BASED TREATMENT MAY OVERCOME THE ADVERSE EFFECT OF FOPNL GENOMIC VARIANT ON THE PROGNOSIS OF MULTIPLE MYELOMA

EHA Library, Katalin Piroska Kiss, 132827

HIGH RESPONSE RATES BUT INEFFECTIVE PRE-SELECTION STRATEGIES FOR TREATMENT WITH HDM AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA BETWEEN 65-70 YEARS IN THE NETHERLANDS

EHA Library, Mirian Brink, 132828

SURVIVAL AND TREATMENT PATTERNS IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA (MM) IN A REAL-WORLD SETTING

EHA Library, ROMAN HAJEK, 132829

FC-GAMMA RECEPTOR POLYMORPHISMS AND PROGRESSION-FREE SURVIVAL: ANALYSIS OF THREE CLINICAL TRIALS OF ELOTUZUMAB IN MULTIPLE MYELOMA

EHA Library, Valerie Poulart, 132830

HIGH EXPRESSION OF AF1Q IS AN ADVERSE PROGNOSTIC FACTOR AND A PREDICTION MARKER OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA

EHA Library, Shotaro Hagiwara, 132831

PHASE 1/2 TRIAL OF LENALIDOMIDE IN COMBINATION WITH CYCLOPHOSPHAMIDE AND PREDNISONE (REP) IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (REPEAT-STUDY)

EHA Library, Lotte van der Wagen, 132832